nCounter® Myeloid Innate Immunity Panel
Helping Your Research
The nCounter® Myeloid Innate Immunity Panel provides comprehensive coverage of myeloid-derived cells in a targeted gene expression assay. These panels can be used with multiple sample types like peripheral blood mononuclear cells (PBMCs) or formalin-fixed paraffin-embedded (FFPE) tissue sections and provide results in less than 24 hours with minimal hands-on time and data analysis.
The Myeloid Innate Immunity Panel is designed to encompass all aspects of the innate immune response of myeloid-derived cells and can be used for basic and translational research in immuno-oncology, autoimmunity, and infectious disease. The panel is curated to include the most current and relevant genes and is available in both human and mouse versions. Use the Myeloid Innate Immunity Panel to study:
- Mechanisms of immune evasion
- Damage response, wound healing & tissue repair
- Immune regulation
- Disease pathogenesis
- Treatment response vs. non-response
How It Works
The nCounter Myeloid Innate Immunity Panels were developed in collaboration with leading experts in the field of immuno-oncology but can be used to study the role of myeloid-derived cells whenever the innate immune system is implicated in the response to a disease or pathogen. Each panel enables characterization of the innate immune response by profiling genes involved in the recruitment and activation of selected myeloid subtypes.
770 genes In 19 different pathways and processes across 7 different myeloid cell types
Rapidly analyze Complex immune responses with publication-quality results next day
Optimized for difficult sample types including FFPE, PBMCs, or FACS sorted cells
Genes represent all major myeloid cell types including neutrophils, eosinophils, mast cells, dendritic cells, monocytes, and macrophages with 19 functional and pathway annotations
Customize with Panel Plus to spike-in up to 55 genes of your choice to tailor the panel for your research project
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma.
Extranodal natural killer T-cell lymphoma (ENKTL) is an aggressive malignancy with a dismal prognosis. In the present study, gene expression profiling was performed to provide more information on ENKTL molecular signature and offer a rationale for further investigation of prognostic markers in ENKTL.
Acute inflammatory profiles differ with sex and age after spinal cord injury.
BACKGROUND: Sex and age are emerging as influential variables that affect spinal cord injury (SCI) recovery. Despite a changing demographic towards older age at the time of SCI, the effects of sex or age on inflammation remain to be elucidated.
The clinical significance of receiving a kidney allograft from deceased donor with chronic histologic changes.
Allograft survival of deceased donor kidneys with suboptimal histology (DRTx/suboptimal histology: >10% glomerulosclerosis, >10% tubulointerstitial scarring, or >mild vascular sclerosis) is inferior to both DRTx with optimal histology (DRTx/optimal histology) and living donor kidneys irrespective of histologic changes (LRTx). In this report, we explored the reasons behind this guarded outcome with a special focus on the role of alloimmunity.